Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2025)

Historic EBT Margin for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 834.87%.

  • Protagonist Therapeutics' EBT Margin fell 1155100.0% to 834.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.61%, marking a year-over-year decrease of 315400.0%. This contributed to the annual value of 64.32% for FY2024, which is 1959100.0% up from last year.
  • Per Protagonist Therapeutics' latest filing, its EBT Margin stood at 834.87% for Q3 2025, which was down 1155100.0% from 623.86% recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' EBT Margin peaked at 82.63% during Q1 2024, and registered a low of 4551.0% during Q2 2022.
  • Its 5-year average for EBT Margin is 661.6%, with a median of 387.75% in 2021.
  • As far as peak fluctuations go, Protagonist Therapeutics' EBT Margin crashed by -101138300bps in 2021, and later surged by 4007000bps in 2022.
  • Over the past 5 years, Protagonist Therapeutics' EBT Margin (Quarter) stood at 431.16% in 2021, then surged by 93bps to 30.46% in 2022, then skyrocketed by 279bps to 54.67% in 2023, then skyrocketed by 48bps to 81.01% in 2024, then tumbled by -1131bps to 834.87% in 2025.
  • Its EBT Margin was 834.87% in Q3 2025, compared to 623.86% in Q2 2025 and 41.15% in Q1 2025.